Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v24-EN Version v4-EN
Language English English
Date Updated 2022-09-27 2022-04-06
Drug Identification Number 00009881 00009881
Brand name PAPAVERINE HYDROCHLORIDE INJECTION USP PAPAVERINE HYDROCHLORIDE INJECTION USP
Common or Proper name PAPAVERINE HCL PAPAVERINE HCL
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients PAPAVERINE HYDROCHLORIDE PAPAVERINE HYDROCHLORIDE
Strength(s) 65MG 65MG
Dosage form(s) LIQUID LIQUID
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging size 2ML 10LIVI 2ML 10LIVI
ATC code A03AD A03AD
ATC description DRUGS FOR FUNCTIONAL BOWEL DISORDERS DRUGS FOR FUNCTIONAL BOWEL DISORDERS
Reason for shortage Shortage of an inactive ingredient or component. Shortage of an inactive ingredient or component.
Anticipated start date 2022-02-11
Actual start date 2022-02-11
Estimated end date 2022-06-17
Actual end date 2022-08-19
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Product is available on allocation at wholesalers, based on 75% of historical volumes.
Health Canada comments